



Express Mail Label No. EV 608865931 US Dated: March 30, 2006

Docket No.: BGNA-013CN
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jeffrey L. Browning *et al.*

Application No.: 10/003211

Confirmation No.: 6970

Filed: October 31, 2001

Art Unit: 1643

For: SOLUBLE LYMPHOTOXIN-BETA
RECEPTORS AS THERAPEUTIC AGENTS
FOR THE TREATMENT OF SYSTEMIC
LUPUS ERYTHEMATOSIS (AS AMENDED)

Examiner: C.H. Yaen

STATEMENT PURSUANT TO 37 CFR 1.821

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Submitted herewith for filing in connection with the above-referenced patent application is a labeled, computer readable copy of the Substitute Sequence Listing included in the application.

I hereby state that I have reviewed the paper copy of the Substitute Sequence Listing contained on pages 1 to 2 of said Sequence Listing, as required by 37 CFR 1.821(c), and have reviewed the computer readable form of the Sequence Listing, as required by 37 CFR 1.821(e), and that the content of the paper and computer readable copies for the above-referenced patent application are the same as required by 37 CFR 1.821(f).

Dated: March 30, 2006

Respectfully submitted,

Amy E. Mandragouras
Registration No.: 36,207
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant